Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study
David Qualls(Memorial Sloan Kettering Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), Alex F. Herrera(City of Hope), Steven M. Bair(University of Colorado Cancer Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Allison M. Bock(Mayo Clinic), Amy Ayers(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Ajay Major(University of Colorado Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew A. Lunning(University of Nebraska Medical Center), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Swetha Kambhampati(City Of Hope National Medical Center), Lei Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Andrew Jallouk(Vanderbilt University Medical Center), Omnia Farahat(The University of Texas MD Anderson Cancer Center), Geoffrey Shouse(City Of Hope National Medical Center)
Cited by 0
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574